

*Press Release*

## **Eurofins MWG Operon and Integrated Genomics cooperate to provide one-stop shopping for complete genome projects**

Ebersberg, Germany and Mount Prospect, IL, USA, 05. October, 2011 – Eurofins MWG Operon and Integrated Genomics have announced a cooperation agreement to combine their expertise in sequencing and analysis services for microbial, fungal and algal organisms. Integrated Genomics, based in Mount Prospect, Illinois, is the leading commercial provider of microbial bioinformatics tools and services based on the ERGO™ genome sequence analysis platform. Eurofins MWG Operon, based in Ebersberg, Germany, and a member of the Eurofins Group, is one of the leading global providers of DNA sequencing services, DNA synthesis products and bioinformatics services for academic and industrial research.

The goal of the cooperation is to provide customers “one-stop-shopping” for complete genome projects that delivers analysis results from the raw extracted DNA. Both companies together serve a worldwide market for their products and services.

“We take specific care to build up a technical and operational pipeline which is suitable to meet our quality standards and the high service level we want to provide to our customers”, says Bruno Poddevin, Eurofins Senior Vice President, Genomic Services. “The specific know-how and bioinformatics capabilities of Integrated Genomics are an excellent fit to our portfolio for prokaryotic, yeast and fungal genome sequencing services.”

“As a leader in the next generation sequencing technology, Eurofins has long been our preferred sequencing partner. With this increased integration we are now able to provide complete genome sequencing and analysis projects for our customers”, says John W. Elling, CEO of Integrated Genomics.

## **About Eurofins MWG Operon**

Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in Europe, the United States, and Asia, is an international provider of DNA sequencing services, DNA synthesis products and bioinformatic services for academic and industrial research. As the pioneering service provider for next generation sequencing, Eurofins MWG Operon has established profound know-how and proprietary protocols to cover a broad range of applications including de novo sequencing, professional project consulting and innovative developments in library generation for a wide range of genomes of any size. The company's strength is its strong customer orientation, fast service, and high quality.

For further information, please visit our website at: [www.eurofinsdna.com](http://www.eurofinsdna.com)

## **About Integrated Genomics**

Integrated Genomics, (IG Assets Inc., Chicago IL) is the leading commercial provider of microbial bioinformatics tools and services based on the ERGO™ genome sequence analysis platform, including ORF-calling, annotation, databases for genome comparison, metabolic analysis and metabolic reconstruction. The company's expertise in microbial genomics includes genome assembly annotations, comparative genomics and custom bioinformatics applications. ERGO™ contains the largest available integration of microbial genome data, including genome-derived metabolic reconstructions representing over 6,800 networked metabolic and non-metabolic pathways.

For further information, please visit our website at: [www.integratedgenomics.com](http://www.integratedgenomics.com)

## **For further information please contact**

### **Eurofins MWG Operon**

Dr. Georg Gradl

Email: [georggradl@eurofins.com](mailto:georggradl@eurofins.com)

Phone: +49 8091 8289945

### **Integrated Genomics**

Vinayak Kapatral, PhD

Email: [vinayak@integratedgenomics.com](mailto:vinayak@integratedgenomics.com)

Phone: +1 224 265 7564

## **Notes for the editor**

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agro science, genomics and central laboratory services.

With about 9,500 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

## **Important disclaimer**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.